US 12,115,161 B2
Prophylactic and/or therapeutic agent for inflammatory diseases which contains pyrrolopyrimidine compound as active ingredient
Tsutomu Takeuchi, Tokyo (JP); Katsuya Suzuki, Tokyo (JP); and Keiko Yoshimoto, Tokyo (JP)
Assigned to Keio University, Tokyo (JP)
Appl. No. 17/054,448
Filed by KEIO UNIVERSITY, Tokyo (JP)
PCT Filed May 10, 2019, PCT No. PCT/JP2019/018710
§ 371(c)(1), (2) Date Jul. 7, 2021,
PCT Pub. No. WO2019/216409, PCT Pub. Date Nov. 14, 2019.
Claims priority of application No. 2018-092068 (JP), filed on May 11, 2018.
Prior Publication US 2021/0393634 A1, Dec. 23, 2021
Int. Cl. A61K 31/519 (2006.01); A61P 37/06 (2006.01)
CPC A61K 31/519 (2013.01) [A61P 37/06 (2018.01)] 13 Claims
 
1. A therapeutic agent for inflammatory disease, comprising: a compound or a salt thereof, or a solvate thereof, the compound represented by a formula (1) below:

OG Complex Work Unit Chemistry
where a ring A denotes a group represented by a formula (A) below:

OG Complex Work Unit Chemistry
where R4 denotes a (C3-6 cycloalkyl) (C1-3 alkyl) amino or nitrile group, L denotes a formula —(CH2)n—, —CH2C(O)—, or —C(O)CH2—, n denotes an integer from 0 to 3, and o denotes a natural number from 1 to 3,
R1 and R2 are same or different from each other, and denote a hydrogen atom or a C1-6 alkyl group,
R3 denotes a C3-6 cycloalkyl group, a C6-10 aryl group optionally substituted by a halogen atom, or a (C6-10 aryl) C1-6 alkyl group, and
m denotes an integer from 0 to 2.